1 2 **Title** 3 Flow cytometry method for absolute counting and single-cell phenotyping of 4 mycobacteria 5 6 **Authors** David A. Barr \*, 1,3,4 Charles Omollo, Mandy Mason, Anastasia Koch, Robert J. 7 Wilkinson, <sup>1,5,6,7</sup> David G. Lalloo, <sup>4</sup> Graeme Meintjes, <sup>1,5</sup> Valerie Mizrahi, <sup>2,1</sup> Digby F. 8 Warner,<sup>2,1</sup> Gerry Davies.<sup>3</sup> 9 10 \* Corresponding author 11 david.barr@liverpool.ac.uk 12 13 **Affiliations:** 14 1. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), 15 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa. 16 2. SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF 17 Centre of Excellence for Biomedical TB Research, Institute of Infectious 18 Disease and Molecular Medicine, Division of Medical Microbiology, 19 Department of Pathology, University of Cape Town, Cape Town, South 20 21 Africa 22 3. Institute of Infection and Global Health, University of Liverpool, Liverpool 23 L7 3EA, UK. 24 4. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, 25 UK. 5. Department of Medicine, University of Cape Town, Cape Town, South 26 27 6. The Francis Crick Institute, London NW11AT, UK. 28 29 7. Department of Medicine, Imperial College, London, W12 0NN, United Kingdom. 30 31

32

## **Abstract**

33

34 Detection and accurate quantitation of viable Mycobacterium tuberculosis is 35 fundamental to understanding mycobacterial pathogenicity, tuberculosis (TB) disease 36 progression and outcomes; TB transmission; drug action, efficacy and drug resistance. 37 Despite this importance, methods for determining numbers of viable bacilli are 38 limited in accuracy and precision owing to inherent characteristics of mycobacterial 39 cell biology – including the tendency to clump, and "differential" culturability – and 40 technical challenges consequent on handling an infectious pathogen under biosafe 41 conditions. We developed an absolute counting method for mycobacteria in liquid 42 cultures using a bench-top flow cytometer, and the low-cost fluorescent dyes Calcein-43 AM (CA) and SYBR-gold (SG). During exponential growth CA+ cell counts are 44 highly correlated with CFU counts and can be used as a real-time alternative to 45 simplify the accurate standardisation of inocula for experiments. In contrast to CFU 46 counting, this method can detect and enumerate cell aggregates in samples, which we 47 show are a potential source of variance and bias when using established methods. We 48 show that CFUs comprise a sub-population of intact, metabolically active 49 mycobacterial cells in liquid cultures, with CFU-proportion varying by growth 50 conditions. A pharmacodynamic application of the flow cytometry method, exploring 51 kinetics of fluorescent probe defined subpopulations compared to CFU is 52 demonstrated. Flow cytometry derived Mycobacterium bovis BCG time-kill curves 53 differ for rifampicin and kanamycin versus isoniazid and ethambutol, as do the 54 relative dynamics of discrete morphologically-distinct subpopulations of bacilli 55 revealed by this high-throughput single-cell technique.

## Introduction

56

57 For more than 100 years, counting Colony Forming Units (CFU) has been the gold-58 standard for quantifying viable Mycobacterium tuberculosis (Mtb) bacilli, both in 59 vitro and ex vivo. However, despite being a methodological foundation underpinning 60 our scientific knowledge of Mtb, CFU counting has several technical and practical 61 limitations, including cost and biosafety implications of maintaining multiple 62 secondary cultures, time interval to results, loss of results from contamination, the 63 inability to distinguish single cells from cell aggregates (clumps), and high intra- and inter-laboratory variation. 1-3 64 65 More fundamentally, under some conditions sub-populations of viable Mtb cells do not form colonies and are therefore unobserved by CFU counting. 4-6 This is of 66 67 particular relevance to tuberculosis (TB) diagnostics and research because of the 68 prevailing theory that the existence of phenotypically heterogenous sub-populations 69 of bacilli – with differential metabolic or growth states – underlie profound aspects of 70 TB disease biology, such as latency and the need for prolonged therapy to effect sterilising cure.<sup>7-10</sup> 71 Improved methods for absolute counting of mycobacteria and phenotypic 72 73 characterisation of subpopulations are therefore desirable. Flow cytometry (FCM) 74 is a well-established technique for counting and characterising eukaryotic 75 cells, and its potential to advance single-cell analyses in microbiology has been discussed in depth. 11,12 Several groups have applied FCM to mycobacteria, including 76 drug sensitivity testing, 13-22 investigation of cell biology, 23-28 early phase diagnostic 77 test development, <sup>29,30</sup> live/dead discrimination, <sup>31,32</sup> and more advanced single-cell 78 phenotyping. <sup>23,33,34</sup> Fluorescent dyes used by prior investigators include: probes of 79 membrane integrity (the nucleic acid stains SYTOX-green, 33 SYTO-9, 24,31,32 SYTO-9 80 BC,  $^{24,32}$  SYTO-16,  $^{16,28}$  SYBR-green I,  $^{30}$  propidium iodide,  $^{16,24,31,32,35}$  TO-PRO-3 81 iodide,<sup>34</sup> and auramine-O<sup>13,35,36</sup>); probes of metabolic activity (esterase substrate dyes 82 fluorescein diacetate, <sup>14,17,20,21,37</sup> and Calcein-violet<sup>33</sup>) and membrane potential 83 (diethyloxacarbocyanine iodide<sup>25,34</sup> & rhodamine-123<sup>27</sup>). In general, absolute bacillary 84 counts have not been derived from FCM; instead, batch measures of fluorescence 85 (e.g. mean fluorescence signal), <sup>13-17,20,21,27,29,37</sup> qualitative read-outs (e.g. scatter-86 plots). 18,26,34 or percentages 23,25,33 are reported. Growth conditions, processing (e.g. 87

89

90

91 92

93

94

95

96 97

98

99

100

101102

103

104

105

106

107

108109

110111

112

113

114

115

116

117

118

119

washes and fixation), and staining protocols vary widely. In the few cases in which the same stains have been used by different groups, results are often contradictory: for example, propidium iodide is reported to stain 0% of heat killed *M. tuberculosis* by one study, 38 and 100% by another. 31 No comparisons of FCM counts with CFU enumerations have been published. The aims of the current study were: 1) To develop and validate a method for absolute counting of mycobacteria in vitro using FCM. 2) To explore the use of fluorescent dyes as probes of cell function to define subpopulations of bacilli in discrete physiological states. 3) To compare dynamics of FCM-defined subpopulations and CFU in liquid cultures over time (growth curves), and over time in the presence of antimycobacterial compounds (time-kill curves). We report a method developed on a low-cost flow cytometer (BD Accuri<sup>TM</sup> C6). using two commercially available fluorescent dyes (SYBR®-Gold and Calcein-AM). The BD Accuri C6 flow cytometer has fixed alignment and pre-optimised detector settings, can record volume of sample processed without use of counting beads, and is small enough to fit on a benchtop or inside a bio-containment hood. SYBR®-Gold (SG), a proprietary cyanine dye (excitation ~495nm, emission ~573nm) with >1000fold fluorescence enhancement when bound to nucleic acid, was designed for use in gel electrophoresis. <sup>39</sup> SG has previously been shown to have substantially greater sensitivity than auramine-O for quantitative fluorescence microscopy of heat-fixed mycobacteria (99% versus 65-80%), 40 but it has not been applied in FCM. Calcein-AM (CA) is a non-polar, lipophilic ester which becomes charged and fluorescent when hydrolysed by 'house-keeping' esterases ubiquitous in the cytoplasm of living cells. 41 Hendon-Dunn and colleagues previously showed that the fluorescence of mycobacteria stained with Calcein-violet-AM correlated with rate of growth in a chemostat and declined with antimicrobial killing of bacilli.<sup>33</sup> In the present study, we applied SG staining after heat killing bacilli to define a total intact cell count denominator; SG staining without heat killing to probe cell membrane integrity as a marker of death or damage; and CA staining without heat killing to probe metabolic activity as a marker of vitality.

121

122

123

124

125126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

Results Setting fluorescence threshold values for FCM events improves validity of absolute bacilli counts The BD Accuri C6 flow cytometer has a fixed dynamic range for voltage and gain, but allows thresholds to be set on two signal values from light scatter and/or fluorescence channels. Signals below the set threshold are not recorded as events. For absolute counting of cells, an optimal threshold is one that is not so high as to exclude true events (signals from cells), yet high enough that it excludes electronic noise and signal from debris (which can otherwise mask true events owing to the refractory period of photodetectors). Typically, thresholds are set on forward and/or side scatter of light (FSC and SSC), as this allows fluorescence-positive and -negative events to be recorded without biasing measurements from the fluorescence channels. We investigated different threshold strategies as follows. Mid-log phase M. bovis BCG cultures were analysed after 2-fold dilution in 0.15% v/v Tween80 PBS solution. These were compared to an identical preparation of cell-free 7H9 broth as a negative control. Permutations of threshold settings were screened. In each case a gate was set around an apparent discrete population of events visible on a log(SSC) by log(FSC) plot, with the gate set manually to minimise the ratio between negative control and the paired BCG sample event counts. The optimal ratio (false positive event count in cell free broth divided by the paired BCG culture count) was defined as the false discovery rate; therefore, threshold parameters which maximised the absolute count in the BCG broth gate and minimised the false discovery rate were sought. Optimal threshold values based on light scatter (FSC and SSC) were inconsistent across replicates and were never associated with false discovery rates less than 10%. By contrast, thresholding on SSC and fluorescence (FL1 533/30 nm) in heat-killed, SYBR-gold stained mid-log BCG consistently reduced the false discovery rate to <0.5%, at the same time increasing absolute cell counts by more than one logarithm compared with thresholding on light scatter alone on the same samples (figure 1). Further, this strategy reduced the coefficient of variation between technical replicates

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176177

178

179

180

to <5%, and gave near perfect linearity across serial dilutions of the same sample  $(R^2>0.99)$  (figure 1). Clumping in mycobacterial broth cultures can be observed and quantified using FCM In all mycobacterial broth cultures tested – M. bovis BCG, M. tuberculosis, and M. *smegmatis*, a second population of events with higher FSC and SSC became evident from early log-phase onwards, developing into the dominant population in mid- or late log-phase (figure 2A). To investigate the nature of these distinct populations, events gated on the two light-scatter populations were sorted for downstream microscopy (figure 2 B&C). This analysis revealed that the higher light-scatter population was composed of clumped cells, despite the fact that all cultures were grown in detergent (Tween80, 0.1% to 0.25% v/v) under continuous agitation (150 to 200 rpm), and notwithstanding the use of sonication prior to flow cytometry. Clumping is a major determinant of CFU count & can be controlled by needle emulsification, but not vortex, sonication or centrifugation Having established the ability to quantify mycobacterial clumping in broth cultures using FCM, we next tested the comparative efficacies of standard microbiological methods for clump dispersal. Vortex and sonication failed to disrupt the clumped population observed on FCM; by contrast, needle emulsification of the broth culture largely eliminated clumping (figure 3A). Disruption of clumps by needle emulsification increased the single-cell population seen on FCM, and therefore the CFU count, by more than 0.5 log (figure 3B). Larger clumps not disrupted even by needle-emulsification emerged in late-stage broth cultures (figure 4). A standard method for preparation of single-cell suspensions of mycobacteria is centrifugation, based on the premise that cell clumps are selectively pelleted by gravity, with single cells remaining in suspension. 42 However, using FCM we found that the ratio of clumps to single-cells was unaffected by centrifugation (figure 5). Growth dynamics of FCM-defined bacilli populations compared to CFU A FCM protocol for absolute counting of bacilli – incorporating SYBR-gold or Calcein-AM staining, needle-emulsification to disperse clumps, and thresholding on

182

183

184

185

186

187

188

189

190

191192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

fluorescence (summarised in figure 6) – was used to explore dynamics of *M. bovis* BCG growth in broth culture. We defined three FCM populations using this protocol: 1. Calcein-AM-positive (CA+) – live sample stained with Calcein-AM, to give an esterase positive, or 'metabolically active', cell count. 2. **SYBR-gold-positive** (SG+) – live sample stained with SYBR-gold, to count cells which have membranes permeable to SYBR-gold, implying membrane damage. 3. **Heat-killed 'total cell count' (HK)** – sample incubated in water-bath at 60°C for 12 minutes to permeabilise cell-membranes, followed by SYBR-gold staining. This is proposed to give a total count of intact cells containing nucleic acid, and therefore provides a denominator for calculating the proportion of cells which are CA+, or SG+, or colony-forming. The selected heat-kill time and temperature were selected as the minimum to reliably maximise the HK count. CFU counts after needle emulsification were determined in parallel (figure 6). In all culture growth phases (lag, log, stationary), the HK cell count was greater than CA+, SG+, or CFU counts (figure 7A), and was accepted as a total cell count. During log-phase, most cells were CA+ and colony forming, with SG+ cells constituting a minority sub-population (figure 7B-D). When entering stationary phase, CA+ and CFU counts started to fall, with a simultaneous rise in SG+ cells, which subsequently became the dominant subpopulation (figure 7B-D). Correlation between CFU and CA+ counts was growth-phase dependent (figure 7E) with close co-variance in early-to-mid-log phase progressively diminishing in late-log (when CFU > CA+) and stationary phase (when CA+ > CFU). Total population growth rate – defined using the instantaneous rate-of-change of the log HK total cell count (the slope of the tangent to the curve at a given timepoint, i.e. the firstderivative) – correlated with the proportion of bacilli which were CA+, but not the proportion of bacilli forming colonies (figure 7F). In vitro pharmacodynamics of M. bovis BCG by CFU and FCM counting

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Having established growth dynamics in the absence of antimicrobials, the FCM count method was applied to pharmacodynamic (PD) time-kill analysis of M. bovis BCG. Starter cultures (100 ml in 500ml tissue culture flasks containing 0.15% v/v Tween 80 7H9 medium) were grown to a density of  $\sim 2 \times 10^5$  CA+ cells per ml, then split into 20ml samples in 50ml conical flasks. Antimicrobials (rifampicin, isoniazid, kanamycin, ethambutol) were added at a range of final concentrations in multiples of their minimum inhibitory concentration (MIC99), and bacilli quantified at 0, 24, 48, 72 and 120 hours using FCM and CFU counting. The experiment was repeated on three separate occasions to ensure independent biological replicates. Raw FCM data plots for heat-killed, Calcein-AM, and SYBR-gold stained preparations from one of three independent replicates are shown for selected conditions in figure 8A-C. Time-kill curves based on absolute counts, and proportions (CA+/HK, SG+/HK, CFU/HK counts), are shown in figures 9A & 9B, respectively. Compared to antimicrobial-free controls, total cell count (HK count) growth was generally impeded by the presence of antimicrobials, although exponential growth still occurred with ethambutol and kanamycin at 0.5xMIC concentration of both antimicrobials. Critically, even at high concentrations of all antimicrobials tested, HK count did not show dramatic reduction over 120 hours of exposure. By contrast, CA+ and CFU counts fell substantially over that time period. Notably, CFU counts declined earlier than CA+ counts for all antimicrobial tested for all inhibitory concentrations. Rifampicin or kanamycin exposure resulted in an earlier decline in CA+ counts than was observed for isoniazid or ethambutol, which at high concentrations showed an initial increase in proportion of cells CA+ at 24 hours, before a sustained fall to day 5. Because a fraction of cells were SG+ under any condition, the major driver of absolute SG+ count was the total cell count, this can be seen in the antimicrobial-free controls where the highest SG+ counts were seen at late stages of growth. The proportion SG+ was, however, antimicrobial dependent: SG+ cells were a majority by day 5 in all supra-MIC concentration conditions, but the rise in the SG+ proportion occurred earlier and was larger for isoniazid and ethambutol than for rifampicin or kanamycin.

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

To summarise differing effects by antimicrobial and subpopulation, sigmoidal  $E_{max}$ models were fitted to the time-kill data (figure 10). Based on CFU time-kill curves, rifampicin, kanamycin, and isoniazid all have similar  $E_{max}$  values, while ethambutol is substantially lower. CA+ time-kill E<sub>max</sub> was higher for rifampicin and kanamycin; and lower for ethambutol and isoniazid. The pattern was reversed for the effect on SG+ proportion. Finally, while the effects of antimicrobials on total cell count (HK count) were modest, they did differ by antimicrobial, with E<sub>max</sub> highest for rifampicin and lowest for ethambutol. Subpopulations of cells by SYBR-gold staining characteristics In addition to count data, qualitative differences in fluorescence were seen in live bacilli stained with SYBR-gold, with two subpopulations of SG+ cells separated by FL1 intensity (most distinct after 72 hours of isoniazid or ethambutol exposure, figure 8C). We hypothesised that two populations of bacilli with different SG staining properties were revealed by the membrane permeabilising effects of these antimicrobials. To investigate this possibility, we developed a protocol for permeabilising M. bovis BCG membranes without bacillary destruction (detailed in methods), and characterised these subpopulations under different antimicrobial conditions by quantifying them and through direct microscopy after cell-sorting. Dual SG+ subpopulations were discriminated by distribution peaks (figure 11A) and were seen under all conditions, including growth without antimicrobial exposure (figure 11B) with one population (labelled P2) returning a mean fluorescence twofold higher than the other (labelled P1) (figure 11A&C). Fluorescent microscopy of cell-sorted samples showed that, compared to P1, P2 bacilli were longer (mean 4.0µm versus 2.5µm), with double the number of fluorescent foci (mean 6.1 versus 3.2) (figure 11D). The ratio of P2 to P1 cells in antimicrobial-free cultures was median 1.75, and non-significantly higher when bacilli were exposed to rifampicin or kanamycin (median 1.83 and 1.86, respectively), but significantly higher after exposure to ethambutol or isoniazid (median 2.11 and 2.00, respectively; p<0.001 for both by rank-sum test). The P2:P1 ratio when bacilli were incubated with both rifampicin and isoniazid matched rifampicin mono-exposure rather than isoniazid mono-exposure (figure 11E).

## Discussion

273

274

275

276277

278

279

280 281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300 301

302

303

304

Detection and accurate quantitation of Mycobacterium tuberculosis is fundamental to understanding TB biology. Growing evidence suggests that culture-based methods detect only a sub-population of bacilli, 4,5 yet these methods remain standard in mycobacterial sciences. By contrast, in response to the analogous problem of differential culturability of microbiota in environmental substrates, FCM has been adopted as an essential method in environmental microbiology research, <sup>60,61</sup> and industry. 62,63 We developed a novel FCM-based method for absolute counting of mycobacteria in liquid cultures. While several groups have reported characterising mycobacteria using FCM, our method is the first to give absolute counts, and can be used to quantify total cell denominator, the presence of cell-clumps, and subpopulations with metabolic activity (using the esterase substrate, Calcein-AM) or membrane permeability (using the nucleic acid stain, SYBR-gold). Our results highlight some critical shortcomings of current 'gold-standard' methods for mycobacteria quantification. We also illustrate how the FCM absolute count method can be used for high-throughput, rapid investigations of phenotypic heterogeneity in mycobacteria and demonstrate the capacity to extract pharmacodynamic data using this approach. Using our FCM method we found that we could reliably identify a subpopulation of the batch culture comprising clumped cells. Further investigations revealed that mycobacterial cultures remain prone to cell clumping in spite of commonly used measures to reduce their formation and to disrupt these before experimentation. We found that sample processing has a major impact on clump-dispersal, such that needle emulsification could increase CFU count approximately two-fold even in early logphase growth. This implies the potential for significant noise and bias in CFU determination, especially for late-log and stationary phase cultures, given that the method depends on serial dilution of dispersed cultures. Our data suggest published protocols<sup>42</sup> for producing single cell suspensions using centrifugation have no effect on the ratio of clumps to single cells. Using the needle-emulsification and FCM counting methods described would be expected to reduce experimental error in mycobacterial research where bacilli counts are needed to standardise starting conditions, or where the number of bacilli is the dependent variable of interest.

306

307

308

309

310311

312

313

314

315

316

317

318

319

320 321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

Further, under antimicrobial-free early-mid log-phase growth conditions, CA+ bacillary counts correlate well with CFU counts and can be obtained within 90 minutes using low-cost reagents indicating that the FCM counting method is a practicable alternative to current culture-based methods of estimating cell numbers. Our FCM method is distinct from previously described mycobacterial FCM protocols primarily because a fluorescence threshold is used to determine when FCM events are recorded. This means that fluorescence-negative events (e.g. a Calcein negative cell) cannot be directly observed but permits accurate absolute counts to be reported for the first time in mycobacterial flow cytometry. Because an absolute cell count denominator can be established with SYBR-gold staining of heat-killed bacilli, the proportion of bacilli with a given characteristic can be ascertained. Importantly, a total cell denominator also allows the proportion of bacilli forming colonies to be measured, which was about 60% in mid-exponential phase of growth in liquid culture. Our pharmacodynamic results build on previous mycobacterial flow cytometry work reported by Hendon-Dunn et al.<sup>33</sup> We replicate their finding that pharmacodynamic flow cytometry profiles based on fluorescent probes of cytoplasmic esterase metabolism and cell wall integrity are different for drugs with different mechanisms of action. We found that the cell wall acting drugs isoniazid and ethambutol were associated with a relatively rapid rise in SG+ cells, while the cytoplasmic targeting rifampicin and kanamycin showed relatively early decline in CA+ bacilli. However, Hendon-Dunn et al. observed only a moderate, concentration-independent effect of rifampicin on Calcein-violet positive bacilli over the first 4 days of exposure. By contrast we found that rifampicin had an early, concentration-dependent effect on CA+ cells, and this effect was substantially greater than for isoniazid. Hendon-Dunn et al. measured relative proportions of Calcein positive and negative cells in cytometry plots, while our method produces absolute cell counts. If antimicrobials have differential effects on the total cell count (which we observed), relative proportions could be unreliable readouts of drug effect (owing to a 'denominator fallacy'). In addition, the manual gating strategy used by Hendon-Dunn et al. does not appear to capture the shift in mean Calcein fluorescence seen under early rifampicin action, whereas the unsupervised classification approach implemented in this method does.

338339

340

341

342

343

344

345

346

347

348

349

350

351

352

353 354

355

356

357

358

359

360

361

362

363

364

365

366

367 368

369

Again, based on absolute counts, we were able to directly and quantitatively compare CFU and FCM sub-population pharmacodynamics. Under all antimicrobial conditions tested, elimination of colony forming bacilli occurred substantially earlier than the decline in CA+ bacilli or the rise in SG+ bacilli. This means that, at some time points a majority of bacilli are structurally intact with evidence of metabolic activity but do not form colonies. Further, we show that pharmacodynamic effect estimates based on FCM-defined subpopulations give different read-outs from those based on CFU counts: the rifampicin effect on CFU elimination is similar to isoniazid, but rifampicin elimination of CA+ bacilli is markedly greater; rifampicin also has a larger effect on total cell count than the other antimicrobials tested. Rather than simply being a rapid surrogate for CFU counts, the FCM method therefore provides information on antimycobacterial drug pharmacodynamics not captured by CFU counting, but it is unknown if this information is clinically meaningful. Terminally injured bacilli may simply retain metabolic activity with residual enzyme activity in a non-viable cell. Alternatively, as non-growing metabolically active (NGMA) cells can be capable of resuscitation,<sup>55</sup> this may represent an adaptive response to antimicrobial stress by reducing the physiological consequences of target inhibition.<sup>56</sup> FCM probes of metabolic and structural integrity would then be more meaningful measures of viability. The latter would be a simple explanation for the lack of correlation between culture-based surrogate endpoints (early bactericidal activity measured using CFU counting, 2-month culture conversion, modelling serial CFU counts or time-topositivity in liquid culture) and probability of achieving sterilising cure in clinical tuberculosis pharmacodynamics<sup>43</sup> and warrants testing in clinical samples. If NGMA bacilli are an adaptive response to antimicrobial exposure then the ability to characterise them using high-throughput methods is critical. By staining live but membrane-permeabilized bacilli with SYBR-gold, we observed two distinct bacilli sub-populations, separated by a two-fold difference in mean fluorescence. We found this phenotype-variation was specifically induced by exposure to isoniazid or ethambutol, but the isoniazid effect was inhibited by the presence of rifampicin. Importantly, the induction of this phenotype could be seen at antimicrobial-conditiontimepoints where >99.9% of CFU were already eliminated (e.g. after 72 hours of isoniazid exposure at 4x MIC concentration). After cell-sorting, bacilli from the twofold brighter subpopulation were found to be longer with double the number of

371

372

373

374

375

376

377

378

379

380

381

382

383

384 385

386 387

388

389

390

391

392 393

394 395

396

397

398

399

400

401

fluorescence foci. Given that SYBR-gold fluoresces when bound to nucleic acid, this implies a bacillary phenotype with double the nucleic acid content, and this phenotypic heterogeneity may therefore represent different numbers of chromosome copies. In a non-human primate model of tuberculosis, "chromosomal equivalents" remain abundant in granulomas that have been sterilised (rendered CFU-negative) by isoniazid therapy. 64 Peaks separated by a 2-fold difference in fluorescent intensity after staining with ethidium bromide or PicoGreen have been used extensively to define multiple chromosome numbers in E. coli. 44-46 Further, several groups have associated polyploidy in *E. coli* with elongated "filamentous" persister cells capable of accelerated antibiotic resistance evolution. 46-48 In the Wayne model of nonreplicating persistence during hypoxia-induced stress, mycobacteria are found to be diploid. 49 In an *in vitro* foamy-macrophage model, intracellular *Mycobacterium avium* has been shown to enter a reversible dormancy state where the bacilli elongate but do not divide (implying they would not form colonies);<sup>57</sup> it is suspected that these elongated, metabolically-active but non-replicating mycobacteria may be polyploid.<sup>50</sup> We speculate that polyploid, metabolically-active but non-colony forming bacilli which are preferentially induced by isoniazid but not rifampic in may be of significant clinical interest. If they represent a drug-tolerant phenotype unobserved by CFU counting, this could explain the fact that, while isoniazid has the most potent early bactericidal activity (EBA, measured by CFU counting), only rifampicin-containing regimens can reliably effect sterilising cure after 6-months ("short-course") therapy. That drug resistant mutants emerge from phenotypically drug tolerant cells has recently been described for clinical isolates of *Staphylococcus aureus*, <sup>58</sup> a similar mechanism might exist for mycobacteria. The spontaneous drug resistance mutation rates for *M. tuberculosis in vitro* range from 10<sup>-7</sup> to 10<sup>-9</sup> and it is somewhat unclear if estimated total mycobacteria numbers in vivo allow for development of multidrug resistance through the simple product of these probabilities<sup>59</sup> – particularly if drug resistance emerges de novo after EBA has eliminated most bacilli observable by culture. A population of bacilli, unobserved by CFU counting but capable of elongation and polyploidy, implies ongoing chromosome replication after antimicrobial exposure and a pool of drug-tolerant cells from which drug resistance could emerge.

403

404

405

406

407 408

409 410

411

412

413

414

415

416 417

418

419

420

421

422

423

424

425

426

427

428

429

430

We used batch cultures in this work which may have limitations. Unexplained variation in FCM sub-population proportions and growth rates between biological replicates, even under antimicrobial-free conditions were seen (e.g. figure 7 B&F). Steady-state cultures – such as the chemostat method used by Hendon-Dunn in their flow-cytometry study – are known to improve reproducibility compared to batch cultures in microbial proteomics and transcriptomics analyses, <sup>51,52</sup> and are likely to be a major advantage in pharmacodynamic studies. Indeed, cell populations in batch cultures can show complex, non-linear growth patterns in cell size and DNA content<sup>44</sup> (which are major read-outs from the current implementation of our FCM absolute count method). However these limitations of batch cultures, match those of currently implemented culture methods in research laboratories and are expected to add noise rather than bias to our results. Overall, our results add to the evidence of limitations in established methods for enumeration of bacilli and support the utility of FCM as a high-throughput, singlecell, culture-independent quantitative tool for the study of mycobacteria in preclinical drug development and ultimately in clinical samples. Methods Cytometry Flow cytometry was performed on a BD Accuri<sup>TM</sup> C6 with manufacturer standard fluorescence detector set-up (FL1, 533/30 nm; FL2, 585/40 nm; FL3, > 670 nm; FL4, 675/25 nm) and data acquisition with BD Accuri<sup>TM</sup> C6 software including recording processed sample volume. Quality assurance was performed using fluorescent beads as per manufacturer protocol. Manual and extended cleaning cycles were performed at the beginning and end of each flow cytometry session with verification of low event rate in filtered PBS before each run. Cell-sorting experiments were performed on a Bio Rad S3 cell sorter or FACS Vantage with voltage and gain set to recreate BD Accuri C6 plots. All microscopy was performed on a Zeiss Axio Observer 7. Sample processing

432

433

434

435

436

437

438 439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

Needle emusfication was performed with 12 passes through a double luer-lock ended, 25 Gauge, 4-inch, micro-emulsifying needle (CAD7974 Sigma Aldrich). Sonication of cultures prior to FCM to assess effect on clump dispersal was performed by submerging 1ml centrifuge tubes attached to a flotation device in a benchtop ultrasonication water-bath three times for 30 second duration (Ultrawave™ U300HD 30 KHZ; Ultrawave, Cardiff, UK). Heat-kill of mycobacterial samples for "HK counts" was by immersion of aliquots in a waterbath at 60°C for 12 minutes. Removal of antimicrobials prior to CFU plating was by pelleting a 1000µL sample (diluted 2fold from 500µL with PBS) at 18000g for 12 minutes, removing 900µL of supernatant, resuspending 100μL residual volume in 900μL of 0.22um filtered 0.15% v/v Tween 80 sterile PBS by pipetting, repeated twice (for 10x10 = 100-fold dilution). This will have diluted antimicrobial in solution (unbound) 200-fold prior to plating. **Culture conditions** Liquid media was prepared from Middlebrook 7H9 media (211887 BD Diagnostics) and 0.22um filtered deionized water according to manufacturer instructions. This was supplemented with 10% v/v Middlebrook OADC (212240 BD Diagnostics), 0.2% v/v glycerol and 0.15% v/v Tween 80. All broth was autoclaved prior to supplementation, and 0.22um filtered prior to use. Liquid cultures were at 37°C in the dark with 150-200rpm agitation in 50ml sterile polyethylene conical flasks in an incubator with an orbital shaking system (model LM-570; MRC Laboratory Instruments Group, London, UK). Middlebrook 7H10 (262710 BD Diagnostics) agar was prepared with 0.22um filtered deionized water according to manufacturer instructions, with v/v 0.5% glycerol added before autoclave sterilisation. When cooled to 45°C, v/v 10% ADC supplement was added and tri-segmented plates poured to depth 5mm. For CFU counting, 10-fold serial dilutions of samples were prepared in 96-well plates using 0.22um filtered 0.15% v/v Tween 80 sterile PBS. Each segment of a plate was inoculated with 50uL of serial dilutions and spread using disposable, sterile loop spreaders. CFU counts were performed with 3-fold technical replicates and counts averaged. Colony counts between 1 and 100 per segment were accepted and, after adjustment for dilution, averages across dilutions were made where available. Counts were performed on 3 occasions (14, 21, and 28 days) to allow colonies to be counted before overgrowth.

464

465

466

467

468

469

470

471

472

473

474

475

476 477

478 479

480

481

482

483 484

485

486

487

488

489

490

491

492

493

Reagents Primary stock dilutions of antibiotic powders were made in 100% DMSO and frozen at-20°C protected from light. Fresh working dilutions were prepared in PBS prior to each experiment, 0.22nm filtered, and stored wrapped in tin foil at 2-5°C refrigeration. Final concentrations of antimicrobials used in M. bovis BCG time-kill experiments are reported in multiples of the MIC as indicated. The MIC were: rifampicin, 0.01µg/ml; isoniazid 0.125μg/ml; kanamycin 1.0μg/ml; ethambutol 1.0 μg/ml. Calcein-AM 50µg vials (ThermoFisher, C3100MP) were reconstituted in 50µL of DMSO on the day of each experiment, further diluted to 200µL with PBS for "working stock". For cell staining,  $5\mu L$  of working stock was added per  $100\mu L$  of sample, with pipette mixing, then incubated in the dark at room temperature for 45-60 minutes before resuspension of bacilli with pipetting. SYBR-gold propriety stock (ThermoFisher, S-11494) was diluted 1000-fold in PBS, aliquoted and frozen at -20°C until use. After thawing aliquot, a further 10-fold dilution (to 10<sup>-4</sup>) in PBS was performed, and 5µL of this working stock added per 100µL of sample to be stained, with pipette mixing, followed by incubation in dark at room temperature for 45-60 minutes before resuspension of bacilli with pipetting. Permeabilization of live cells For the investigation of SG stained subpopulations, published methods for permeabilizing mycobacterial cell walls were reviewed; those with highest reported success and best description of validation 53,54 were taken forward for testing and adaptation. Permutations of paraformaldehyde / ammonium chloride fixation, ethanol, hydrochloric acid, detergents, and lysozyme were tested at different concentrations, incubation times, and temperatures also assessed iteratively. This led to a final method for reliable permeabilization of BCG bacilli without substantial cell loss, such that over 80% of bacilli could be SYBR-gold stained (compared to the heat-killed total cell count denominator gold standard). In the final method, a 500uL sample was diluted to 1ml with PBS v/v 0.15%Tween 80, without wash step or fixation. After needle emulsification, lysozyme was added to final conc 0.1 mg/ml, and the sample incubated for 45 minutes at 37°C. 500µl triton-X-100 was then added to final concentration v/v 0.2%. This was pelleted (16000g, 5 min) and re-suspended in 500µl

495

496

497

498

499 500

501

502

503

504

505

506

507 508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

PBS-tween; 40µl working stock SYBR-gold added and incubated at room temperature for 2-4 hours. Data analysis Raw flow-cytometry data was extracted from .fcs files exported from BD Accuri C6 software using flowCore (v 2.0.1) Bioconductor package<sup>65</sup> and all analysis performed in Rstudio v1.1.463. Rather than using manually placed gates to classify events, unsupervised machine-learning classification algorithms were used. For main flow cytometry plots (figure 8) k-means clustering was applied to FL1 height, FL1 area, and Side-Scatter height observations from one replicate using kmeans() function in stats package<sup>66</sup> in R, and the clustering solution applied to all the data. Optimal number of clusters was determined empirically using NbClust() function from NBClust package<sup>67</sup> in R. To separate P2 and P1 events in permeabilized SG-stained live cells (figure 11), a Gaussian Mixture Model was fit to all the data with 2 component distributions using normalmixEM() function in mixtools package.<sup>68</sup> In all FCM scatter plots, log transformations to base e (natural logarithms) are presented unless otherwise indicated (plots with log transformations to base 2 are used in cases where a doubling of fluorescence is a specific feature of interest). Time-kill curves were summarised in descriptive plots (figure 9) using non-parametric loess regression models. To extract summary measures of antimicrobial effect, the time-kill data was modelled using a linear mixed-effects model, with a fixed effect of intercept, and random slopes for antibiotic condition and replicate:  $logcellcount \sim intercept + (timepoint | condition) + (timepoint | rep)$ This captures the crossed experimental design where each replicate was assessed under each antimicrobial condition, and each replicate assessed under each condition. The antibiotic condition effect, defined as slope gradient for the time-kill curve, was then extracted, independent of replicate effect, from the model as a summary PD measure. Because the dependent variable is on a log scale this assumes a monoexponential decline in cell populations under antimicrobial action. The dependent variables assessed were CFU count, CA+ count, HK count, and proportion SG+. The R package *lme4* was used for this modelling.<sup>69</sup>

- Antimicrobial effects extracted from these models were related to drug concentration
- for each antimicrobial using a standard sigmoid  $E_{max}$  PK/PD model, of form:

$$E = \frac{E_{max} \cdot C^n}{EC_{50}^n + C^n}$$

525 Where E is the PD effect (the slope gradient estimates by mixed-effects modelling 526 above), C is the drug concentration (known from experimental condition), and the 527 remaining parameters are estimated from the data:  $E_{max}$  (maximum achievable effect 528 of antimicrobial),  $EC_{50}$  (the drug concentration where half of  $E_{max}$  is obtained), and n529 (a scaling parameter). Models were fitted using non-linear least squares (nls() function 530 in R. 531 Fluorescence profiles of bacilli (figure 11D) were extracted as .csv files from microscopy images using Fiji (ImageJ). 70 This raw data was processed using a 532 custom-built function defining local maxima in smoothed profiles to count fluorescent 533 534 peaks. 535

Acknowledgments:

The work was supported by Wellcome Trust fellowship 105165/Z/14/A.

RJW receives support from Francis Crick Institute which is funded by Wellcome Trust [FL0010218], UKRI [FC0010218], CRUK [FC0010218] and also support from Wellcome Trust [104803, 203135].

Author contributions:

DAB, GD, DL, RJW, and GM conceived of the approach and initiated the project. DAB, DFW, VM, GD and GM conceived specific methods and experiments. DAB, CO, AK, and MKM designed and performed the experiments. DAB analysed data and wrote the manuscript with input from all authors.

Data availability:

Data and analysis scripts are available in an Open Science Framework repository here <a href="https://osf.io/gwhpd/?view\_only=02a61e8134cc4adca3840df604e0e38b">https://osf.io/gwhpd/?view\_only=02a61e8134cc4adca3840df604e0e38b</a>

Competing interests:

Authors declare no competing interests

## References


- 1. Sutton S. Accuracy of plate counting. *Journal of Validation Technology* 2011; (Summer 2011): 42-6.
- 2. Hafner R, Cohn JA, Wright DJ, et al. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. *Am J Respir Crit Care Med* 1997; **156**(3 Pt 1): 918-23.
- 3. Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. *J Antimicrob Chemother* 2001; **47**(2): 177-82.
- 4. Chengalroyen MD, Beukes GM, Gordhan BG, et al. Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. *Am J Respir Crit Care Med* 2016; **194**(12): 1532-40.
- 5. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. *Am J Respir Crit Care Med* 2010; **181**(2): 174-80.
- 6. Dhillon J, Fourie PB, Mitchison DA. Persister populations of *Mycobacterium tuberculosis* in sputum that grow in liquid but not on solid culture media. *J Antimicrob Chemother* 2014; **69**(2): 437-40.
- 7. Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. *Clin Microbiol Rev* 2006; **19**(3): 558-70.
- 8. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. *Int J Tuberc Lung Dis* 2012; **16**(6): 724-32.
- 9. Wayne LG, Sohaskey CD. Nonreplicating persistence of *Mycobacterium tuberculosis*. *Annu Rev Microbiol* 2001; **55**: 139-63.
- 10. Esmail H, Barry CE, 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. *Drug Discov Today* 2012; **17**(9-10): 514-21.
- 11. Davey HM, Kell DB. Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses. *Microbiol Rev* 1996; **60**(4): 641-96.
- 12. Muller S, Nebe-von-Caron G. Functional single-cell analyses: flow cytometry and cell sorting of microbial populations and communities. *FEMS Microbiol Rev* 2010; **34**(4): 554-87.
- 13. Akselband Y, Cabral C, Shapiro DS, McGrath P. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry. *J Microbiol Methods* 2005; **62**(2): 181-97.
- 14. DeCoster DJ, Vena RM, Callister SM, Schell RF. Susceptibility testing of *Mycobacterium tuberculosis*: comparison of the BACTEC TB-460 method and flow cytometric assay with the proportion method. *Clin Microbiol Infect* 2005; **11**(5): 372-8.
- 15. Fredricks BA, DeCoster DJ, Kim Y, Sparks N, Callister SM, Schell RF. Rapid pyrazinamide susceptibility testing of *Mycobacterium tuberculosis* by flow cytometry. *Journal of Microbiological Methods* 2006; **67**(2): 266-72.
- 16. Govender SdP, S.J.; van de Venter, M.; Hayes, C. Antibiotic susceptibility of multidrug resistant *Mycobacterium tuberculosis* using flow cytometry. *Medical Technology SA* 2010; **24**(2): 25-8.
- 17. Reis RS, Neves I, Lourenco SLS, Fonseca LS, Lourenco MCS. Comparison of Flow Cytometric and Alamar Blue Tests with the Proportional Method for Testing Susceptibility of *Mycobacterium tuberculosis* to Rifampin and Isoniazid. *Journal of Clinical Microbiology* 2004; **42**(5): 2247-8.
- 18. Piuri M, Jacobs WR, Jr., Hatfull GF. Fluoromycobacteriophages for rapid, specific, and sensitive antibiotic susceptibility testing of *Mycobacterium tuberculosis*. *PLoS One* 2009; **4**(3): e4870.
- 19. Moore AV, Kirk SM, Callister SM, Mazurek GH, Schell RF. Safe determination of susceptibility of *Mycobacterium tuberculosis* to antimycobacterial agents by flow cytometry. *J Clin Microbiol* 1999; **37**(3): 479-83.

- 20. Bownds SE, Kurzynski TA, Norden MA, Dufek JL, Schell RF. Rapid susceptibility testing for nontuberculosis mycobacteria using flow cytometry. *J Clin Microbiol* 1996; **34**(6): 1386-90.
- 21. Norden MA, Kurzynski TA, Bownds SE, Callister SM, Schell RF. Rapid susceptibility testing of *Mycobacterium tuberculosis* (H37Ra) by flow cytometry. *J Clin Microbiol* 1995; **33**(5): 1231-7.
- 22. Vena RM, Munson EL, DeCoster DJ, et al. Flow cytometric testing of susceptibilities of *Mycobacterium avium* to amikacin, ciprofloxacin, clarithromycin and rifabutin in 24 hours. *Clin Microbiol Infect* 2000; **6**(7): 368-75.
- 23. Hammond RJ, Baron VO, Oravcova K, Lipworth S, Gillespie SH. Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you? *J Antimicrob Chemother* 2015; **70**(10): 2823-7.
- 24. Gonzalez YMJA, Zaragoza-Contreras R, Guadarrama-Medina R, et al. Evaluation of the cell growth of mycobacteria using *Mycobacterium smegmatis* mc2 155 as a representative species. *J Microbiol* 2012; **50**(3): 419-25.
- 25. Shi L, Gunther S, Hubschmann T, Wick LY, Harms H, Muller S. Limits of propidium iodide as a cell viability indicator for environmental bacteria. *Cytometry A* 2007; **71**(8): 592-8.
- 26. James BW, Williams A, Marsh PD. The physiology and pathogenicity of *Mycobacterium tuberculosis* grown under controlled conditions in a defined medium. *J Appl Microbiol* 2000; **88**(4): 669-77.
- 27. Resnick MS, S.; Bercovier,H. Bacterial membrane potential analysed by spectrofluorocytometry. *Current Microbiology* 1985; **12**: 183-6.
- 28. Ibrahim P, Whiteley AS, Barer MR. SYTO16 labelling and flow cytometry of *Mycobacterium avium*. *Lett Appl Microbiol* 1997; **25**(6): 437-41.
- 29. Yi WC, Hsiao S, Liu JH, et al. Use of fluorescein labelled antibody and fluorescence activated cell sorter for rapid identification of Mycobacterium species. *Biochem Biophys Res Commun* 1998; **250**(2): 403-8.
- 30. Qin D, He X, Wang K, Tan W. Using fluorescent nanoparticles and SYBR Green I based two-color flow cytometry to determine *Mycobacterium tuberculosis* avoiding false positives. *Biosens Bioelectron* 2008; **24**(4): 626-31.
- 31. Soejima T, Iida K, Qin T, Taniai H, Yoshida S. Discrimination of live, anti-tuberculosis agent-injured, and dead *Mycobacterium tuberculosis* using flow cytometry. *FEMS Microbiol Lett* 2009; **294**(1): 74-81.
- 32. Burdz TVN, Wolfe J, Kabani A. Evaluation of sputum decontamination methods for *Mycobacterium tuberculosis* using viable colony counts and flow cytometry. *Diagnostic Microbiology and Infectious Disease* 2003; **47**(3): 503-9.
- 33. Hendon-Dunn CL, Doris KS, Thomas SR, et al. A flow cytometry method for rapidly assessing M. tuberculosis responses to antibiotics with different modes of action. *Antimicrob Agents Chemother* 2016.
- 34. Shapiro HM. Flow cytometry of bacterial membrane potential and permeability. *Methods Mol Med* 2008; **142**: 175-86.
- 35. Ryan C, Nguyen BT, Sullivan SJ. Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop encapsulation. *J Clin Microbiol* 1995; **33**(7): 1720-6.
- 36. Scott LE, Gous N, Cunningham BE, et al. Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa. *J Clin Microbiol* 2011; **49**(12): 4356-60.
- 37. Kirk SM, Schell RF, Moore AV, Callister SM, Mazurek GH. Flow cytometric testing of susceptibilities of *Mycobacterium tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. *J Clin Microbiol* 1998; **36**(6): 1568-73.
- 38. Pina-Vaz C, Costa-Oliveira S, Rodrigues AG, Salvador A. Novel method using a laser scanning cytometer for detection of mycobacteria in clinical samples. *Journal of Clinical Microbiology* 2004; **42**(2): 906-8.
- 39. Tuma RS, Beaudet MP, Jin X, et al. Characterization of SYBR Gold nucleic acid gel stain: a dye optimized for use with 300-nm ultraviolet transilluminators. *Anal Biochem* 1999; **268**(2): 278-88.

- 40. Ryan GJ, Shapiro HM, Lenaerts AJ. Improving acid-fast fluorescent staining for the detection of mycobacteria using a new nucleic acid staining approach. *Tuberculosis* (*Edinb*) 2014; **94**(5): 511-8.
- 41. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. *J Immunol Methods* 1990; **133**(1): 87-97.
- 42. Saito K, Warrier T, Somersan-Karakaya S, et al. Rifamycin action on RNA polymerase in antibiotic-tolerant *Mycobacterium tuberculosis* results in differentially detectable populations. *Proc Natl Acad Sci U S A* 2017; **114**(24): E4832-E40.
- 43. Davies GR. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. *Tuberculosis (Edinb)* 2010; **90**(3): 171-6.
- 44. Akerlund T, Nordstrom K, Bernander R. Analysis of cell size and DNA content in exponentially growing and stationary-phase batch cultures of *Escherichia coli*. *J Bacteriol* 1995; **177**(23): 6791-7.
- 45. Ferullo DJ, Cooper DL, Moore HR, Lovett ST. Cell cycle synchronization of *Escherichia coli* using the stringent response, with fluorescence labeling assays for DNA content and replication. *Methods* 2009; **48**(1): 8-13.
- 46. Barrett TC, Mok WWK, Murawski AM, Brynildsen MP. Enhanced antibiotic resistance development from fluoroquinolone persisters after a single exposure to antibiotic. *Nat Commun* 2019; **10**(1): 1177.
- 47. Bos J, Zhang Q, Vyawahare S, Rogers E, Rosenberg SM, Austin RH. Emergence of antibiotic resistance from multinucleated bacterial filaments. *Proc Natl Acad Sci U S A* 2015; **112**(1): 178-83.
- 48. Sun L, Alexander HK, Bogos B, Kiviet DJ, Ackermann M, Bonhoeffer S. Effective polyploidy causes phenotypic delay and influences bacterial evolvability. *PLoS Biol* 2018; **16**(2): e2004644.
- 49. Wayne LG. Synchronized replication of *Mycobacterium tuberculosis*. *Infect Immun* 1977; **17**(3): 528-30.
- 50. Ditse Z, Lamers MH, Warner DF. DNA Replication in *Mycobacterium tuberculosis*. *Microbiol Spectr* 2017; **5**(2).
- 51. Bull AT. The renaissance of continuous culture in the post-genomics age. *J Ind Microbiol Biotechnol* 2010; **37**(10): 993-1021.
- 52. Hoskisson PA, Hobbs G. Continuous culture--making a comeback? *Microbiology* 2005; **151**(Pt 10): 3153-9.
- 53. Carr EL, Eales K, Soddell J, Seviour RJ. Improved permeabilization protocols for fluorescence in situ hybridization (FISH) of mycolic-acid-containing bacteria found in foams. *J Microbiol Methods* 2005; **61**(1): 47-54.
- 54. Cimino M, Alamo L, Salazar L. Permeabilization of the mycobacterial envelope for protein cytolocalization studies by immunofluorescence microscopy. *BMC Microbiol* 2006; **6**: 35.
- 55. Evans JC, Trujillo C, Wang Z, et al. Validation of CoaBC as a bactericidal target in the coenzyme A pathway of *Mycobacterium tuberculosis*. *ACS Infect Dis* 2016; **2**(12): 958-68.
- 56. Manina G, McKinney JD. A single-cell perspective on non-growing but metabolically active (NGMA) bacteria. *Curr Top Microbiol Immunol* 2013; **374**: 135-61.
- 57. Caire-Brandli I, Papadopoulos A, Malaga W, et al. Reversible lipid accumulation and associated division arrest of *Mycobacterium avium* in lipoprotein-induced foamy macrophages may resemble key events during latency and reactivation of tuberculosis. *Infect Immun*. 2014;82(2):476-490.
- 58. Liu J, Gefen O, Ronin I, Bar-Meir M, Balaban NQ. Effect of tolerance on the evolution of antibiotic resistance under drug combinations. *Science*. 2020;367(6474):200-204.
- 59. McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. Mutation rate and the emergence of drug resistance in *Mycobacterium tuberculosis*. *J Antimicrob Chemother*. 2014;69(2):292-302
- 60. Porter J, Deere D, Hardman M, Edwards C, Pickup R. Go with the flow use of flow cytometry in environmental microbiology. *FEMS Microbiology Ecology* 1997; **24**(2): 93-101.

- 61. Wang Y, Hammes F, De Roy K, Verstraete W, Boon N. Past, present and future applications of flow cytometry in aquatic microbiology. *Trends Biotechnol* 2010; 28(8): 416-24.
- 62. Hassard FW, R. Understanding the Use of Flow Cytometry for Monitoring of Drinking Water.: Department for Environment, Food & Rural Affairs Drinking Water Inspectorate / Cranfield Water Science Institute, 2019.
- 63. Laplace-Builhe C, Hahne K, Hunger W, Tirilly Y, Drocourt JL. Application of flow cytometry to rapid microbial analysis in food and drinks industries. *Biol Cell* 1993; 78(1-2): 123-8.
- 64. Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. *Nat Med.* 2014;20(1):75-79.1.
- 65. Hahne F, LeMeur N, Brinkman RR, et al. flowCore: a Bioconductor package for high throughput flow cytometry. *BMC Bioinformatics* 2009; **10**: 106.
- 66. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
- 67. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set. *2014*. 2014;61(6):36.
- 68. Benaglia T, Chauveau D, Hunter DR, Young D. mixtools: An R Package for Analyzing Finite Mixture Models. *Journal of Statistical Software*, 2009; 32(6), 1-29. http://www.jstatsoft.org/v32/i06/.
- 69. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software*, 2015; **67**(1), 1–48. doi: 10.18637/jss.v067.i01.
- 70. Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise, et al. Fiji: an open source platform for biological image-analysis. *Nature Methods* 2012; **9(7)**: 676-682.


Figure 1. Comparison of 3 thresholding strategies in heat killed and SYBR-gold stained mid-log phase BCG broth culture.



A. Example FCM plots for three thresholding strategies (rows 1-3) applied to *M. bovis* BCG broth culture (column 1) and cell-free broth (cell-free negative control, column 2). Counts are extracted for the gated population (events within dashed red line), which is placed to maximise the count in BCG broth and minimise the count in the cell-free control. Recorded events in the low light scatter value thresholding (first row) are dominated by debris/noise, seen as a dense population with low SSC and FSC values in lower left quadrant; this is equally apparent in the cell-free control. Higher light scatter thresholding (second row) excludes these events, but still records a substantial portion of higher SSC/FSC noise (seen in cell-free control), and the threshold level appears to bisect the 'real' cell population; *i.e.*, losing cells from analysis. By contrast, the thresholding based on fluorescence (third row) is qualitatively better, with very few false positive events in the cell-free control, and detection of a discrete cell population in BCG broth which is not artificially bisected.

**B.** Greater internal consistency in the FL1/SSC thresholding strategy, with less error across serial dilutions of a M. bovis BCG culture. Quantitative evidence of improved absolute count validity includes a lower false discovery rate (FDR, defined as false positive cell count in cell-free control divided by paired cell count from broth); lower coefficient of variation (CV, calculated by standard deviation/mean from 5 technical replicates, averaged for 3 biological replicates); and higher  $R^2$  from linear fit across serial dilution series (one biological replicate as shown in figure; p<0.001 for F test comparing FL1/SCC to either FSC/SSC strategy; 95% confidence intervals for linear fit shown with grey shaded areas).


Figure 2. Identifying mycobacterial clumping with FCM.




A. 2D-density plots of FSC v SSC on log scale for a culture of *M. bovis* BCG grown with 0.15% v/v Tween80 at 180 rpm. Plots are from samples taken at 48, 96, 144, and 240 hours after bacilli were sub-cultured from a log-phase starter culture into pre-warmed broth (early, early-mid, late-mid and late log-phase, respectively). Samples were diluted 10-fold or 100-fold (later samples) in 0.25% v/v Tween80 PBS and sonicated for 60 seconds prior to flow cytometry. The tail of higher SSC and FSC events at 48-hours is seen to develop into a discrete second subpopulation by 96-hours, which continues to expand into a higher SSC and FSC region and become the predominant subpopulation by the end of log-phase. All plots are constructed from 5000 events.

- **B**. *M*. *tuberculosis* and *M*. *smegmatis* processed as above (both mid-late log phase) also develop dual populations separating on FSC and SSC, replicating the *M*. *bovis* BCG findings.
- C. *M. smegmatis* sample was run on a BioRad S3 cell sorter with P1 and P2 sorted for downstream fluorescence microscopy (representative images shown). *M. smegmatis* was used for cell sorting owing to concerns about aerosolising *M. tuberculosis* or *M. bovis* BCG. P1 comprised majority single cells or doublets, while P2 comprised majority clumps (manually quantified from fluorescence microscopy images).

Figure 3. Needle-emulsification, but not vortex or sonication, disrupt clumps and increases cell counts



log Forward-Scatter




Mid-log phase culture of *M. smegmatis* grown in 0.15% v/v Tween80 7H9 with 150 rpm agitation and diluted 10-fold in 0.15% v/v Tween80 PBS and stained with Calcein-AM prior to FCM on a BD Accuri C6. Data acquisition with thresholds SSC>1000 and FL1>2000. Samples were processed by 60 second vortex, or by 60 second vortex followed by 5 minutes sonication in water bath, or by both these methods followed by needle emulsification (12 passes through a double Luer lock-ended, 25 Gauge, 4-inch, micro-emulsifying needle with a reinforcing bar (Cadence Inc.).

**A.** Two populations are seen which are differentiated by light-scatter: single cells (P1) and clumps (P2). Qualitatively, vortex and sonication processing did not disrupt P2 population (clumps), but needle emulsification (far right plot) shifted events from predominantly P2 (clumps) to predominantly P1 (single cells).

**B**. Counts of CFUs or FCM events with three-replicates from 3 independent cultures (purple, green, yellow dots). Emulsification resulted in a greater number of CFU and decreased the P2 count while increasing the P1 count substantially. The apparent total cell counts were increased by emulsification by an order of magnitude: both CFU count and total flow cytometry CA positive count increased by half to one unit on log scale. This can be interpreted as resulting from clumps (P2 population) being disaggregated into single cells (P1). The p-values were determined from repeated-measures ANOVA by cell-disruption method.


Figure 4. Clumps which are resistant to disruption by emulsification eventually emerge in late logphase cultures.



**A.** *M. bovis* BCG culture in 0.15% v/v Tween80 7H9 with 150 rpm agitation and diluted 10-fold in 0.15% v/v Tween80 PBS before bacilli were heat-killed and stained with SYBR-gold. Samples were needle-emulsified (12 passes through a double Luer lock-ended, 25 Gauge, 4-inch, micro-emulsifying needle) prior to FCM on BD Accuri C6; data acquisition with thresholds SSC>1000 and FL1>1000. Timepoints are days post inoculation into prewarmed broth from log phase starter culture. A long tail of clumps, extending into the upper-right quadrant of higher SSC and FSC, emerges from around day 9, at OD<sub>600</sub> ~ 0.3. Clumps were defined as events with SSC and FSC values greater than 10-log and 11-log (events in upper right quadrant of plots).

**B**. Clumps and single cells quantified by flow cytometry (four independent replicates of data represented by A; replicates are shown with different colours). Emulsification appears able to disrupt clumps until late log phase (~day 8), when both the ratio of clumps to single cells and size (approximated by mean FSC) of clumps rise rapidly. Line of best fit with 95% confidence interval band is a LOESS regression line ignoring dependence by replicate.


Figure 5. Ratio of clumped to single-cell *M. smegmatis* is not altered by low-g centrifugation.



Three mid-log phase M. smegmatis cultures grown in 0.05% Tween80 7H9 with continuous agitation at 150 rpm (3 biological replicates shown in blue, green and red), processed three ways. **Control sample**:  $10^{-1}$  dilution in 0.1% Tween80 PBS, no physical disruption. **Centrifuge sample**: 10ml + 5ml +

- **A**. Qualitatively, the FSC by SSC flow plots were similar for centrifuge method and control, compared to the needle-emulsified sample where the cell-clump population (P2) was not evident.
- **B**. The ratio of clumps to single cells (p2:p1) was the same in the control and centrifuge preparations, but was much lower (and with less variation across replicates) with emulsification. Apparent cell counts were lower with centrifugation (owing to loss of cells in pellet) and higher with emulsification (owing to disruption of clumps). Three independent culture replicates (read, blue, and green; each processed 3 times in each condition for technical replicates); p-values from repeated measures ANOVA (technical replicates nested within culture replicates).

Figure 6. Schematic for final FCM count SOP used in *M. bovis* BCG culture growth & time-kill dynamics experiments






Figure 7. Bacillary population dynamics during standard growth in culture

Four independent *M. bovis* BCG cultures (replicates i to iv), grown in 50ml 0.15% v/v Tween80 7H9, 500ml tissueculture flasks at 150 rpm agitation, were serially quantified by CFU and FCM counts (method outlined in figure 6) between 2 and 15 days after inoculation into pre-warmed broth from a log phase starter culture. (**A**) Using the heat-killed SYBR-gold stained (HK) cell count as total cell denominator, the proportion of bacilli which were Calcein-AM positive (CA+), colony-forming (CFU), and permeable to SYBR-gold without heat-killing (SG+) are shown over time post inoculation (**B-D**); each replicate is plotted using a different colour; LOESS line-of-best-fit and 95% CI shown for the observations aggregated across replicates. Linear correlation between log CA+ and log CFU counts was strong (**E**), but with a dependency on phase of growth (time in days from inoculation shown by colour; non-constant variance (NCV) test for heteroscedasticity, p=0.03, dashed lines are +/- 1 SD of residual variation). Rate of population growth is defined as instantaneous rate of change in total cell count (slope of the tangent to the curve at a given timepoint; *i.e.*, first derivative of the growth curve). Rate of total population growth was regressed on proportion of bacilli able to form colonies, or on proportion CA+ (**F**), at any given timepoint, with each replicate (i to iv, again shown by colour) allowed to differ by intercept but not slope.

log<sub>2</sub> FL1 (533/30nm)

Heat-killed (HK) preparation, stained with SYBR-gold Live preparation, stained with Calcein-AM (CA+) Live preparation, stained with SYBR-gold (SG+) В 24h 72h 120h 20 20 log<sub>2</sub> Side-Scatter log<sub>2</sub> Side-Scatter log<sub>2</sub> Side-Scatter 20 15 H0.5 20 20 


Figure 8. Raw FMC plots of HK, CA+, and SG+ events for selected antimicrobial conditions and timepoints.

log<sub>2</sub> FL1 (533/30nm)

Raw FMC data from one of three independent replicates. SYBR-gold stained heat-killed (HK) samples (A, left), Calcein-AM stained live samples (B, middle), and SYBR-gold stained live samples (C, right), by antimicrobial condition (rows) and time-point (hours) post introduction of antimicrobials (columns). Antimicrobial indicated by letter prefix (E, ethambutol; H, isoniazid; K, kanamycin; R, rifampicin) and concentration in multiples of MIC<sub>99</sub> by suffix letter (*e.g.*, R4 = rifampicin at 4x MIC). FCM events in each plot are coloured by K-means clustering on all light-scatter and fluorescence dimensions – an unsupervised classification (machine learning) algorithm used to define subpopulations without subjective manual placement of gates.


log<sub>2</sub> FL1 (533/30nm)

Figure 9. Time-kill curves generated through FCM defined cell populations and CFU counts



Data from three replicates. Counts (left panel) and proportions (right panel) by cell population [CA+ = Calcein-AM-stained in live samples; CFU = colony forming units; SG+ = SYBR-gold-stained in live samples; HK = SYBR-gold-stained in heat-killed samples] over time by antimicrobial condition. Antimicrobial indicated by letter in rows (E, ethambutol; H, isoniazid; K, kanamycin; R, rifampicin; CTRL, antimicrobial-free ["Nil Abx"] broth) and concentration in multiples of MIC in columns. Non-parametric Loess regression line and shaded 95% confidence intervals shown. Proportions are derived using HK count as a total cell count denominator (*i.e.* CA+/HK, SG+/HK, CFU/HK).


Figure 10. E<sub>max</sub> models applied to time-kill data from FCM defined cell population and CFU counts



The time-kill data in figure 9 were modelled using a linear mixed-effects model to extract an estimate of mono-exponential elimination rate for each antimicrobial condition as a summary pharmacodynamic (PD) measure for each FCM defined cell population and CFU counts. Antimicrobial effects extracted from these models were related to drug concentration for each antimicrobial using a standard sigmoid  $E_{max}$  PK/PD model, shown here for each antimicrobial (columns) and each cell population (rows).

<sup>\*</sup> A sigmoidal  $E_{max}$  model could not be fit for rifampicin %SG+ growth rate data due to non-convergence; the fit shown is from a model excluding the outlier data point at concentration 0.005 mg/ml (-5.3 on log scale). When this data point (indicated in grey) was excluded, the model converged.

Figure 11. Distinct pharmacodynamics of SYBR-gold-positive sub-populations



A. FCM plot for ethambutol-treated (4x MIC, 48 hours), SYBR-gold stained live bacilli. Two discrete sub-populations are visible, separated by approximately two-fold difference in fluorescence. These sub-populations were visible in most ethambutol- or isoniazid-treated cultures, but not readily visible in rifampicin or kanamycin FCM plots (figure 8), **B**. After membrane permeabilization at room temperature, these distinct sub-populations are visible under all conditions including the antimicrobial-free control. C. Clustering algorithm (Gaussian mixture model) used to label bacilli as P1 (lower SG fluorescence) or P2 (higher SG fluorescence). **D**. P1 and P2 bacilli sorted for downstream microscopy show different morphologies. A random selection of bacilli images from sorted P1 and P2 sub-populations were measured along their longitudinal axis using ImageJ to assess length and fluorescence profile (two examples shown). P2 bacilli were longer than P1 bacilli (mean 4.0um versus 2.5um) and contained approximately double the number of fluorescent 'beaks' (mean 6.1 versus 3.2: peaks defined by local maxima in a LOESS smoothing function applied to the fluorescence profile plots). E. The ratio of P2:P1 bacillary counts was dependent on antimicrobial: isoniazid and ethambutol exposure caused a relative rise in P2 bacilli compared to control, but the same effect was not seen for rifampicin or kanamycin. For the rifampicin plus isoniazid (Rif + Inh) combination treatment, the P2:P1 ratio matched the ratio obtained for rifampicin monotherapy, rather than isoniazid. All pvalues were determined from a linear regression of P2:P1 ratio on antimicrobial category, with the antimicrobial-free control as reference category. F. Non-parametric Loess regression fitting P2:P1 ratio to log2 concentration (black line with shaded 95% confidence interval) for each antimicrobial condition suggests the pharmacodynamic effect may be non-linearly dependent on concentration.